
Upfront Combos Show Promise in Prostate Cancer, But Questions Remain
In an interview with Targeted OncologyTM, Biren Saraiya, MD, medical oncologist at Rutgers Cancer Institute, discusses how he sees findings from the AMPLITUDE trial evaluating niraparib (Zejula) and abiraterone acetate (Zytiga) plus prednisone for the …